Neurocrine Biosciences Inc NBIX:NASDAQ

Last Price$84.88NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/16/22

Today's Change+0.76(0.90%)
Bid (Size)$80.43 (14)
Ask (Size)$85.40 (7)
Day Low / High$82.82 - 85.23
Volume496.2 K

Neurocrine Biosciences' Positive Huntington Disease Results Should Help Add $300 Million to Drug Sales, RBC Says

11:38AM ET 12/08/2021 MT Newswires
Neurocrine Biosciences' (NBIX) positive results from a late-stage study of its experimental Ingrezza valbenazine drug in adults with chorea tied to Huntington disease are adequate to support a label expansion and should add about $300 million to out-year revenue for the drug, according to RBC Capital Markets.

"With shares having come down substantially following a 3Q sales number we believe disappointed the Street, we believe today's de-risking HD data should clear the way for the stock to appreciate and better reflect Ingrezza's TD/HD growth prospects," RBC Analysts Brian Abrahams, Stephen Mallon and Leonid Timashev said in a note emailed Wednesday.

The investment firm lifted its price target on the drugmaker's stock to $122 from $119 with an outperform rating.

Neurocrine Biosciences shares were up nearly 3% in recent trading.

Price: 84.33, Change: +2.08, Percent Change: +2.53